Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is a strong and growing company that provides specialized software solutions for the public and private sectors. They have a proven track record of success and are well-positioned for future growth and expansion. However, there are potential risks, such as reliance on government agencies and competition, that investors should be aware of. With a solid financial foundation and promising growth strategies, Cellebrite is a positive investment opportunity in the AI and digital forensic industry.

Bears say

Cellebrite DI is facing potential headwinds from multiple factors, including a weaker sales outlook with missed revenue forecasts and risks related to the company's dependence on law enforcement and government agencies. Additionally, changes in public sentiment and potential funding disruptions for its customers could impact future growth. Furthermore, increased competition in the market and potential risks of a data breach could also affect the company's performance. These risks could lead to a decline in key financial metrics and investor sentiment, negatively impacting the stock's valuation.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.